NavDX A Case-Based Discussion On The Utility Of NavDX AHNS H&N Conference
This is a discussion of the use of NavDX and covers real-life cases.
1 Hour Video
Detection of HPV-Driven OPSCC: Clinical Evidence of an Innovative Blood Test - A Case-based Discussion of the Clinical Role of NavDx in Managing OPSCC Faculty:
Dr. Chris Holsinger, Professor of Otolaryngology, Stanford University School of Medicine, Stanford, CA
Dr. Glenn Hanna, Director, Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute
Dr. Bhisham Chera, Professor of Radiation Oncology & Otolaryngology Medical University of South Carolina, Charleston, SC
AHNS 11th International Head and Neck Cancer Conference, July 8-12, 2023
Take care, God Bless
Russ
Comments
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.9K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 398 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 794 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 63 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 540 Sarcoma
- 733 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards